Achilles Therapeutics plc (ACHL) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ACHL Hot Sheet
Join SI Premium – FREE
Achilles Therapeutics plc (NASDAQ: ACHL) reported Q3 EPS of ($0.48), $0.07 worse than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Achilles Therapeutics plc (ACHL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACM Research (ACMR) Tops Q3 EPS by 6c ; Offers Guidance
- Gold Royalty Corp. (GROY) Tops Q3 EPS by 1c
- Targa Resources (TRGP) Reports Q3 results
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
